Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
BG Medicine, Inc. (BGMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/23/2016 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/05/2016 15-12B Form 15-12B - Securities registration termination [Section 12(b)]
04/29/2016 10-K/A Annual Report for the period ended December 31, 2015 [amend]
04/04/2016 10-K Annual Report for the period ended December 31, 2015
04/01/2016 EFFECT Form EFFECT - Notice of Effectiveness
03/31/2016 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
03/31/2016 8-K Quarterly results
03/29/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
03/29/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
03/29/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
03/29/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
03/29/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
03/29/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
03/29/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
03/29/2016 POS AM Form POS AM - Post-Effective amendments for registration statement
02/04/2016 8-K Form 8-K - Current report
01/19/2016 SC 13G/A Empery Asset Management, LP reports a 5% stake in BG Medicine, Inc.
12/23/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "BG Medicine Withdraws 510 Premarket Notification for Proposed Additional Indication for the BGM Galectin-3 ® Test Waltham, MA, December 23, 2015 - BG Medicine, Inc. today announced that it has submitted to the FDA a notice of withdrawal of its 510 premarket notification filing with the US Food and Drug Administration that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3 ® Test for a potential new indication for use as an aid in the assessment of the near-term risk of fatal cardiovascular events in older adults who have no prior history of cardiovascular disease, cerebrovascular disease or vascular disease. As previously disclosed, on March 31, 2015, BG Medicine filed for 510 premarket notification with the FDA in order to obtain regulatory clearance for th..."
12/04/2015 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter of Deloitte & Touche LLP to the Securities and Exchange Commission"
11/30/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "License and Distribution Agreement Amended Adoption of Automated Testing for Galectin-3 by Reference Laboratories Expected to Expand Waltham, Mass., November 30, 2015 - BG Medicine, Inc. , the developer of the BGM Galectin-3 ® Test, today announced an amendment to its license and distribution agreement for Galectin-3. Amendment to License and Distribution Agreement In support of the commercialization of automated testing for galectin-3, BG Medicine and Abbott have amended their License and Distribution Agreement in regard to the product fees paid to BG Medicine by Abbott for galectin-3 tests sold by Abbott to reference laboratories, while retaining the previously negotiated product fee for the other customer segments. “We believe that this modification to our agreement will open up a new c..."
11/23/2015 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/20/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Non-Employee Director Compensation Policy, effective November 18, 2015"
11/17/2015 8-K Quarterly results
Docs: "BG Medicine Reports Third Quarter 2015 Financial Results Waltham, Mass., November 17, 2015 - BG Medicine, Inc. , the developer of the BGM Galectin-3 ® Test, today reported financial results for the three and nine months ended September 30, 2015. “Our operating results in the third quarter of 2015 reflect our ongoing efforts to extend our cash runway through the prudent and disciplined management of our resources, “ said Paul R. Sohmer, M.D., President and CEO of BG Medicine . “The commercialization of automated testing for galectin-3 in the U.S. was initiated in the third quarter. As a result, we continue to expect that product fees generated through the initial sales of automated tests for galectin-3 in the U.S. and payable to the Company by Abbott will be reported next quarter.” Third Qu..."
11/16/2015 10-Q Quarterly Report for the period ended September 30, 2015
09/25/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/15/2015 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "BG MEDICINE TO BEGIN TRADING ON THE OTCQB"
08/21/2015 SC 13G Empery Asset Management, LP reports a 9.5% stake in BG Medicine, Inc.
08/18/2015 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "Underwriting Agreement, between the Company and Roth Capital Partners, LLC",
"Amended and Restated Certificate of Designations of Series A Preferred Stock of BG Medicine, Inc. filed with the Secretary of State of the State of Delaware on August 18, 2015",
"Form of Prefunded Common Stock Purchase Warrant issued to certain purchasers in the Offering",
"Form of Common Stock Purchase Warrant issued to the purchasers in the Offering",
"BG Medicine Announces Proposed Underwritten Public Offering WALTHAM, Mass. - August 12, 2015 - , BG Medicine, Inc., the developer of the BGM Galectin-3 ® Test, today announced that it intends to offer and sell equity securities in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners is acting as the sole manager for the offering. The Company is offering Series A units, consisting of common stock and warrants. The Company is also offering Series B units, in lieu of Series A units, to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially ...",
"BG Medicine Prices Underwritten Public Offering WALTHAM, Mass. - August 13, 2015 - BG Medicine, Inc., the developer of the BGM Galectin-3 ® Test, today announced the pricing of an underwritten public offering of its equity securities. Roth Capital Partners is acting as sole manager for the offering. The company is offering 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit. The company is also offering 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the company's o..."
08/18/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C"
08/18/2015 10-Q/A Quarterly Report for the period ended June 30, 2015 [amend]
08/17/2015 10-Q/A Quarterly Report for the period ended June 30, 2015 [amend]
08/14/2015 10-Q Quarterly Report for the period ended June 30, 2015
08/14/2015 8-K Quarterly results
Docs: "BG Medicine Provides Business Update and Reports Second Quarter 2015 Financial Results Focus Shifts to Support of Market Introduction of Automated Galectin-3 Test in U.S. Operating Cash Burn for Second Quarter of 2015 Reduced by 68% from Second Quarter of 2014"
08/03/2015 SC 13D/A AGTC ADVISORS FUND LP reports a 27.6% stake in BG Medicine, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy